LATE-BREAKING ABSTRACT: ENERGITO: Efficacy and safety of once-daily combined tiotropium + olodaterol versus twice-daily combined fluticasone propionate + salmeterol

Conclusions: This study suggests that using LABA/ICS, F+S in this study, in moderate/severe COPD may provide sub-optimal lung-function improvements compared to T+O. Funding: Boehringer Ingelheim.

Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Beeh, K.-M., Derom, E., Echave-Sustaeta, J., Groenke, L., Hamilton, A., Zhai, D., Bjermer, L. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research